Zvi Gregorio Fridlender

Prof. Fridlender is a physician and a scientist at the Hebrew University Hadassah Medical School in Jerusalem, Israel. He is a leader in the field of Immunology and Immunotherapy of lung cancer and mesothelioma. His work led to several key discoveries in tumor immunology, mostly in lung cancer, and the characterization of the diversity and importance of neutrophils in cancer. Prof. Fridlender has published 67 peer-reviewed articles and book chapters, mostly in tumor immunology and immunotherapy, including several highly-cited articles on the role of regulatory myeloid cells in cancer, especially neutrophils. In 2009 Prof. Fridlender published a groundbreaking article in the prestigious Cancer Cell journal, highlighting for the first time the unique plasticity of neutrophils in cancer. This paper was cited over 400 times and has been described by the editors of cancer cells as one of their landmark papers in their centennial issue. This article was followed by a series of articles on the role and diversity of tumor-related neutrophils. In a recent Cancer-Research review he introduced the term "immunosuppressive switch" as an important hallmark of cancer development.

As a physician, Prof. Fridlender is known as one of the leading Internal Medicine and Pulmonology physicians. He founded and led the Hadassah Center for COPD and smoking-related damages and serves as the General Secretary of the Israel Society of Pulmonary Medicine since 2013. In addition, Prof Fridlender serves on the managing committee of MYE-EUNITER – a European action on myeloid regulatory cells, and since 2015 as a member of the program committee of the American Thoracic Society.